Medy-Tox Inc. Logo

Medy-Tox Inc.

Biopharmaceutical firm developing botulinum toxins, HA fillers, and dermocosmetics.

086900 | KO

Overview

Corporate Details

ISIN(s):
KR7086900008
LEI:
Country:
South Korea
Address:
충청북도 청원군 오창읍 각리1길 78 (주)메디톡스, 청원군

Description

Medy-Tox Inc. is a biopharmaceutical company focused on the research, development, and commercialization of biologic products. Its primary offerings are centered on botulinum toxin type A (BTX-A) formulations, including Neuronox®, INNOTOX®, Coretox®, and NEWLUX®, which are used for both aesthetic and therapeutic applications. The company is noted for developing the world's first liquid-injectable botulinum toxin. In addition to its toxin portfolio, Medy-Tox manufactures and markets a line of hyaluronic acid (HA) dermal fillers, such as Neuramis®, Atiere, and Potenfill. The company's product range also extends to dermocosmetics under the NEURADERM brand.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 00:00
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean 5.3 KB
2025-08-26 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.5 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 2.7 MB
2025-08-11 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.4 KB
2025-07-22 00:00
자기주식처분결과보고서
Korean 18.2 KB
2025-07-16 00:00
주요사항보고서(자기주식처분결정)
Korean 57.4 KB
2025-07-02 00:00
주식등의대량보유상황보고서(약식)
Korean 62.4 KB
2025-05-14 00:00
분기보고서 (2025.03)
Korean 2.0 MB
2025-05-12 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.5 KB
2025-04-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.3 KB
2025-03-28 00:00
정기주주총회결과
Korean 24.0 KB
2025-03-25 00:00
자기주식취득결과보고서
Korean 28.9 KB
2025-03-20 00:00
감사보고서제출
Korean 26.6 KB
2025-03-20 00:00
사업보고서 (2024.12)
Korean 604.4 KB
2025-03-13 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.9 KB

Automate Your Workflow. Get a real-time feed of all Medy-Tox Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medy-Tox Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medy-Tox Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.